One investment company can proceed with most of its counterclaims against another for a dispute in a biomedical securities transaction, the Court of Chancery ruled Thursday.

But Judge Paul R. Wallace wrote for the Court of Chancery that the tribunal lacks jurisdiction over one breach-of-contract claim brought by Casla Bio Holdings and Casla Bio GP LLC against CLP Toxicology Inc. because it involved what financial information should be considered when calculating a contingent payment.